Ovarian suppression with tamoxifen reduced recurrence in some premenopausal breast cancer cases

Visit www.ecancer.org for more.
At a press conference at SABCS 2014, Dr Prudence Francis (Peter MacCallum Cancer Centre, Melbourne, Australia) presents data on adding ovarian suppression to tamoxifen reduced recurrence for some women with premenopausal breast cancer.
A 35 percent decrease in risk of breast cancer recurrence was observed for premenopausal women who received chemotherapy for early-stage, hormone receptor-positive breast cancer and were assigned exemestane with ovarian suppression compared with those assigned tamoxifen.